Choice of imputation method for missing metastatic status affected estimates of metastatic prostate cancer incidence

J Clin Epidemiol. 2023 Mar:155:22-30. doi: 10.1016/j.jclinepi.2022.12.008. Epub 2022 Dec 17.

Abstract

Objectives: To study how handling missing data on M stage in a clinical cancer register affects estimates of incidence of metastatic prostate cancer.

Study design and setting: Estimates of age-standardized incidence of metastatic prostate cancer were obtained by the use of data in a population-based clinical cancer register in Sweden and using four methods for imputation of missing M stage. Adjusted survival was used to compare men with known and imputed M stage.

Results: The proportion of men with missing M stage was high (66%) and varied according to the risk group and over calendar time. The estimated incidence of metastatic disease varied depending on imputation method, with all methods indicating a decreasing incidence over time. A combination of deterministic imputation (DI) and multiple imputation (MI) produced adjusted survival curves for men with imputed M stage that best resembled the survival for men with known M stage.

Conclusions: Plausible estimates of incidence of metastatic prostate cancer in clinical cancer registers can be obtained by the use of a combination of DI of missing M stage and MI.

Keywords: Imaging; Incidence; Metastases; Missing data; Prostate cancer; TNM staging.

MeSH terms

  • Data Collection
  • Humans
  • Incidence
  • Male
  • Prostatic Neoplasms* / epidemiology
  • Registries
  • Risk Factors